Diurnal profile of interstitial glucose following dexamethasone prophylaxis for chemotherapy treatment of gynaecological cancer
Authors:
- 25 June 2018
- journal article
- research article
- Published by Wiley in Diabetic Medicine
- Vol. 35 (11) , 1508-1514
Abstract
Aims: Hyperglycaemia, a side‐effect of acute glucocorticoid exposure, is associated with poor outcome in those undergoing chemotherapy. The incidence, risk factors and diurnal profile of glucocorticoid‐induced glucose dysregulation in the context of chemotherapy treatment remain incompletely understood.Methods: Blinded continuous interstitial glucose monitoring was performed on 16 women without diabetes for 24 h prior to and 5 days following carboplatin/paclitaxel chemotherapy combined with dexamethasone treatment for gynaecological cancer. At the end of the treatment period, glucose data were analysed and integrated with baseline metabolic and anthropomorphic variables.Results: 15/16 (94%) women exhibited elevated glucose levels (> 11.1 mmol/l). Peak glucose levels were highest on the day of treatment (median 14.45 mmol/l, range 10.2–22.2 mmol/l) and total time spent with an elevated interstitial glucose level was highly variable (median 3.6 h, range 0.0–55.1 h). Peak interstitial glucose levels occurred predominantly, but not exclusively, in the afternoon (13.00–15.00) and evening (19.00–22.00); however elevated levels were noted throughout the 24‐h period. Baseline HbA1c was independently associated with severity and duration of elevated glucose levels in a regression adjusted for baseline BMI.Conclusions: These data report for the first time that high glucose levels are encountered by nearly all women following this regimen, the severity and duration of which are independently associated with HbA1c. Further work is required to determine if controlling glucose levels during treatment influences outcome.Keywords
This publication has 26 references indexed in Scilit:
- Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patientsDiabetology & Metabolic Syndrome, 2013
- A Randomized Controlled Trial of an Intensive Insulin Regimen in Patients With Hyperglycemic Acute Lymphoblastic LeukemiaClinical Lymphoma Myeloma and Leukemia, 2012
- Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysisPLOS ONE, 2012
- Glucocorticoid-induced diabetes mellitus in patients with systemic lupus erythematosus treated with high-dose glucocorticoid therapyLupus, 2011
- Prevalence of long-term oral glucocorticoid prescriptions in the UK over the past 20 yearsRheumatology, 2011
- Metformin and Cancer Risk in Diabetic Patients: A Systematic Review and Meta-analysisCancer Prevention Research, 2010
- Glucose as a prognostic factor in non-diabetic women with locally advanced cervical cancer (IIB–IVA)Gynecologic Oncology, 2010
- Glucose as a prognostic factor in ovarian carcinomaCancer, 2009
- Antecedent Hyperglycemia Is Associated With an Increased Risk of Neutropenic Infections During Bone Marrow TransplantationDiabetes Care, 2008
- GLUT1 mRNA and Protein Expression in Ovarian Borderline Tumors and CancerOncology, 2004